Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inhaled Ad5-nCoV (Convidecia Air) Booster Trial
NCT05124561Phase 3Withdrawn
- Sponsor
- CanSino Biologics Inc.
- Start
- Dec 2021
- Primary completion
- Apr 2022
- Modality
- Vaccines & Immunotherapeutics
01
Overview
Phase 3, randomised, double-blind trial of ad5-ncov in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by CanSino Biologics Inc. Primary endpoints: Incidence of COVID-19 cases and Incidence of SAE. Planned start Dec 2021; status: withdrawn.
02
Drugs
ad5-ncov
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05124561.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05124561.